BRPI0415833A - derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos - Google Patents

derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos

Info

Publication number
BRPI0415833A
BRPI0415833A BRPI0415833-4A BRPI0415833A BRPI0415833A BR PI0415833 A BRPI0415833 A BR PI0415833A BR PI0415833 A BRPI0415833 A BR PI0415833A BR PI0415833 A BRPI0415833 A BR PI0415833A
Authority
BR
Brazil
Prior art keywords
lower alkyl
hydrogen
treatment
trifluoromethyl
halogen
Prior art date
Application number
BRPI0415833-4A
Other languages
English (en)
Inventor
Simona Maria Ceccarelli
Emmanuel Pinard
Henri Stalder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0415833A publication Critical patent/BRPI0415833A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE TRIAZA-ESPIROPIPERIDINA PARA USO COMO INIBIDORES DE GLYT-1 NO TRATAMENTO DE DISTúRBIOS NEUROLóGICOS E NEUROPSIQUIáTRICOS". A invenção refere-se aos compostos da fórmula geral em que A-Aé -CH~ 2~-CH~ 2~-, -CH~ 2~-CH~ 2~-CH~ 2~-, -CH~ 2~-O- ou -0-CH~ 2~-; X é hidrogênio ou hidróxi; R¬ 1¬ é arila ou heteroarila, substituída ou não substituída por um ou mais substituintes, selecionados dentre o grupo consistindo de alquila inferior, alcóxi inferior, halogênio ou trifluorometila; R¬ 2¬ é arila ou heteroarila, substituída ou não substituída por um ou mais substituintes, selecionados dentre o grupo consistindo de alquila inferior, alcóxi inferior, halogênio ou trifluorometila, ou é alquila inferior, -(CH~ 2~)~ n~-Cicloalquila, -(CH~ 2~)~ n~-CF~ 3~, -(CH~ 2~)~ p~O-alquila inferior, -(CH~ 2~)~ 1,2~-fenila, opcionalmente substituída por halogênio, alquila inferior, alcóxi inferior ou trifluorometila, ou é -(CH~ 2~)~ p~-NR<39>R<39><39>, em que R<39> e R<39><39> formam juntos com o N-átomo um anel heterocíclico, selecionado dentre o grupo consistindo de piperidina, morfolina, tiomorfolina ou 1,1-dioxo-tiomorfolina; R¬ 3¬, R¬ 4¬ são independentemente um de cada outro hidrogênio, alquila inferior, fenila ou benzila; R¬ 5¬ é hidrogênio, alquila inferior ou benzila; R¬ 6¬ é hidrogênio ou alquila inferior; n é 0,1 ou 2; e p é 2 ou 3; e aos sais de adição de ácido farmaceuticamente aceitáveis dos mesmos para o tratamento de psicoses, dor, disfunção neurodegenerativa em memória e aprendizagem, esquizofrenia, demência e outras doenças em que os processos cognitivos são prejudicados como distúrbios do déficit de atenção ou mal de Alzheimer.
BRPI0415833-4A 2003-10-23 2004-10-14 derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos BRPI0415833A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03024415 2003-10-23
PCT/EP2004/011552 WO2005040166A1 (en) 2003-10-23 2004-10-14 Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
BRPI0415833A true BRPI0415833A (pt) 2007-01-02

Family

ID=34486099

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415833-4A BRPI0415833A (pt) 2003-10-23 2004-10-14 derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos

Country Status (19)

Country Link
US (1) US7189850B2 (pt)
EP (1) EP1678177B1 (pt)
JP (1) JP4490434B2 (pt)
KR (1) KR100798161B1 (pt)
CN (1) CN100467468C (pt)
AR (1) AR046186A1 (pt)
AU (1) AU2004283843B2 (pt)
BR (1) BRPI0415833A (pt)
CA (1) CA2543308C (pt)
CO (1) CO5690643A2 (pt)
DE (1) DE602004010419T2 (pt)
ES (1) ES2297502T3 (pt)
IL (1) IL174734A (pt)
MX (1) MXPA06004305A (pt)
NO (1) NO20061419L (pt)
RU (1) RU2006117368A (pt)
TW (1) TW200526662A (pt)
WO (1) WO2005040166A1 (pt)
ZA (1) ZA200603221B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5266042B2 (ja) 2005-04-11 2013-08-21 エール ユニヴァーシティ 統合失調症前駆症の治療方法
DE102005038141A1 (de) * 2005-08-12 2007-02-15 Grünenthal GmbH Substituierte 8-(3-Aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-on-Derivate
AU2007222446B2 (en) * 2006-03-08 2011-08-18 F. Hoffmann-La Roche Ag 4-amino-1,5-substituted 1,5-dihydro-imidazol-2-ones
WO2007104776A1 (en) * 2006-03-16 2007-09-20 Glaxo Group Limited N-phenyl-2-0x0-1,4-diazaspir0 [4.5] dec-3-en-1-yl acetamide derivatives and their use as glycine transporter inhibitors
GB0607398D0 (en) * 2006-04-12 2006-05-24 Glaxo Group Ltd Compounds
WO2007149873A2 (en) * 2006-06-20 2007-12-27 Wyeth Kv1.5 potassium channel inhibitors
US20090325993A1 (en) * 2007-02-01 2009-12-31 Nadia Mamoona Ahmad GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
GB0701955D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
GB0701985D0 (en) * 2007-02-01 2007-03-14 Glaxo Group Ltd Compounds
JP2010517964A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド GlyT1トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
US20100048656A1 (en) * 2007-02-01 2010-02-25 Nadia Mamoona Ahmad Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
AR065095A1 (es) * 2007-02-01 2009-05-13 Glaxo Group Ltd COMPUESTO DE ARIL-OXO-DIAZAESPIRO, INTERMEDIARIO PARA SU SíNTESIS, USO DEL MISMO PARA PREPARAR UN MEDICAMENTO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR GLYT1, COMPOSICION FARMACEUTICA Y ASOCIACION QUE LO COMPRENDEN.
JP2010517962A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド GlyT1トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
MX2009012685A (es) * 2007-05-31 2009-12-14 Sepracor Inc Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina.
BRPI0812833A2 (pt) 2007-07-03 2014-12-09 Hoffmann La Roche 4-imidazolinas e seu uso como antidepressivos
CN101784533B (zh) 2007-08-22 2013-08-21 艾博特股份有限两合公司 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途
WO2009034062A1 (en) * 2007-09-11 2009-03-19 Glaxo Group Limited Compounds which inhibit the glycine transporter and uses thereof in medicine
US20090077077A1 (en) * 2007-09-18 2009-03-19 Gerhard Geldenbott Optimal selection of MSAG address for valid civic/postal address
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
EP2271625B1 (en) 2008-04-01 2012-09-12 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
NZ593279A (en) 2009-01-27 2013-03-28 Hoffmann La Roche Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014001457A (es) 2011-08-05 2014-08-21 Abbvie Deutschland Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia.
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
JP2015157764A (ja) * 2012-06-14 2015-09-03 大正製薬株式会社 グリシントランスポーター阻害物質
CA2906157C (en) 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
JP6430483B2 (ja) 2013-03-15 2018-11-28 ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. 化学療法の間の正常細胞の一時的な保護
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2016533375A (ja) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
CN106061969B (zh) 2014-01-06 2019-10-29 阿尔戈么迪克斯有限公司 Trpa1调节剂
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
EP3134406A1 (en) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3215500A1 (en) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted azetidinyl compounds as glyt1 inhibitors
RS60825B1 (sr) 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー1 セラピューティクス, インコーポレイテッド 癌の治療に対する併用療法
EP3645001B1 (en) 2017-06-29 2024-07-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
KR102962306B1 (ko) 2018-08-24 2026-05-08 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69803653T2 (de) * 1997-12-05 2002-08-29 F. Hoffmann-La Roche Ag, Basel 1,3,8-Triazaspiro[4,5]decan-4-on-derivate
SI0921125T1 (en) * 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
PT1594840E (pt) * 2003-02-17 2007-01-31 Hoffmann La Roche Derivados de piperidina-benzenossulfonamida

Also Published As

Publication number Publication date
EP1678177A1 (en) 2006-07-12
ZA200603221B (en) 2009-04-29
CO5690643A2 (es) 2006-10-31
CN100467468C (zh) 2009-03-11
AU2004283843A1 (en) 2005-05-06
CN1871238A (zh) 2006-11-29
EP1678177B1 (en) 2007-11-28
MXPA06004305A (es) 2006-06-05
US7189850B2 (en) 2007-03-13
AU2004283843B2 (en) 2010-04-22
KR100798161B1 (ko) 2008-01-28
CA2543308C (en) 2012-03-06
RU2006117368A (ru) 2007-12-10
US20050107373A1 (en) 2005-05-19
WO2005040166A1 (en) 2005-05-06
CA2543308A1 (en) 2005-05-06
AR046186A1 (es) 2005-11-30
KR20060076317A (ko) 2006-07-04
JP4490434B2 (ja) 2010-06-23
JP2007509097A (ja) 2007-04-12
IL174734A0 (en) 2006-08-20
DE602004010419T2 (de) 2008-10-09
ES2297502T3 (es) 2008-05-01
TW200526662A (en) 2005-08-16
IL174734A (en) 2010-05-31
DE602004010419D1 (de) 2008-01-10
NO20061419L (no) 2006-07-14

Similar Documents

Publication Publication Date Title
NO20061419L (no) Triaza-spiropiperidinderivater for anvendelse som Glyt-1-inhibitorer i behandling av nevrologiske og nevropsykiatriske lidelser
BRPI0407543A (pt) derivados de piperidina-benzenossulfonamida
Alagarsamy et al. Synthesis and pharmacological investigation of novel 4-benzyl-1-substituted-4H-[1, 2, 4] triazolo [4, 3-a] quinazolin-5-ones as new class of H1-antihistaminic agents
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacêutico
EA200501516A1 (ru) Производные 2,3,6-тризамещённого-4-пиримидона
BRPI0112475B8 (pt) n-óxido de derivados 4-fenil-piridina como antagonista de receptor nk1, seu medicamento, seu processo de preparação e seus usos
BRPI0213393B8 (pt) derivados de éter alquílico, ou um de seus sais, processo para produzir um derivado de éter alquílico, derivado de alquil-amida, ou um de seus sais, e, composição farmacêutica
NO20073667L (no) [4-(heteroaryl) piperazin-1-yl]-(2,5-substituert-fenyl)metanonderivater som glycintransportor 1(GLYT-1)- inhibitorer for behandling av neurologiske og neuropsykiatriske lidelser
BRPI0413536B8 (pt) derivados de 1-benzoil-piperazina, seu uso e medicamento que os compreende
ATE545413T1 (de) Antagonisten des opioidrezeptors
CY1116350T1 (el) Mopφh συνκρυσταλλου «α» της [4-(3-φθορο-5-τριφθορομεθυλο-πυριδιν-2-υλο)-πιπεραζιν-1-υλο]-[5-μεθανοσουλφονυλο-2-((s)-2,2,2-τριφθορο-1-μεθυλο-αιθοξυ)-φαινυλο]-μεθανονης με μεθυλοπαραμπεν
BRPI0607600A2 (pt) derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina
DE60111464D1 (de) Azabicycloalkan-Derivate zur Verwendung als Inhibitoren der Serotonin-Wiederaufnahme und als 5HT2a Antagonisten
JP4762250B2 (ja) フェニル−ピペラジンメタノン誘導体
ATE475640T1 (de) Antagonisten des opioidrezeptors
BR0317422A (pt) Compostos de n-(indoletil) cicloamina
EA200970596A1 (ru) Соединения с сочетанием антагонистической активности в отношении каннабиноидных рецепторов сви ингибирующей активности в отношении ацетилхолинэстеразы
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
EP1473295A4 (en) CONDENSED BICYCLIC PYRIMIDINE DERIVATIVES
WO2007054444A3 (en) 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives
Barbay et al. Synthesis and characterization of 5, 6, 7, 8-tetrahydroquinoline C5a receptor antagonists
BRPI0414460A (pt) compostos derivados de carboxamida do tipo de amida, composição farmacêutica e respectivo uso
Alagarsamy et al. Synthesis of 4-butyl-1-substituted-4H-[1, 2, 4] triazolo [4, 3-a] quinazolin-5-ones as new class of H1-antihistaminic agents
BRPI0414597A (pt) derivados de benzofurano do tipo carbamoìla
AR038342A1 (es) Derivados piridin-amido

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.